Takara Bio, Sloan-Kettering to develop NHL gene therapy

MemorialSloan.jpg

Japanese biotech firm Takara Bio has announced a collaboration with Memorial Sloan-Kettering Cancer Center in the United States to begin the process of running a clinical trial for a non-Hodgkin's lymphoma therapy involving gene therapy.

The therapy in question will utilize Chimeric Antigen Receptor (CAR) technology, which has been in development by Memorial Sloan-Kettering since 2007. They have been exploring the efficacy of a CAR targeting CD19, a protein expressed on the surface of certain B lymphocytes. Until now, CD-19 CAR gene therapy has only undergone early-stage testing for certain patients with leukemia, with encouraging results.

Together, Takara Bio and Memorial Sloan-Kettering will apply for gene therapy clinical research in Japan by using Sloan-Kettering's previously gathered data on CD19 CAR, and Takada will develop the retrovirus vector necessary in gene therapy to gain access to the cell.

Source: Takara Bio

LymphomaInfo Social